New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2013
05:55 EDTAVEO, AVEO, CAH, CAH, ABC, ABC, AET, AET, CVS, CVS, BMY, BMY, JPM, JPM, MCK, MCK, CLSN, CLSNCBI to host a forum
6th Annual Forum on Oncology Market Access & Payer Strategies is being held in Philadelphia on January 30-31.
News For MCK;CLSN;AVEO;CAH;ABC;AET;CVS;BMY;JPM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
January 13, 2015
07:42 EDTBMY, CVSJPMorgan to hold a conference
33rd Annual Healthcare Conference is being held in San Francisco on January 12-15 with webcasted company presentations to begin on January 13 at 10:30 am; not all company presentations may be webcasted. Webcast Link
07:05 EDTJPMJPMorgan volatility increases into Q4 and outlook
Subscribe for More Information
07:04 EDTAVEOAveo Pharmaceuticals estimates Q4 cash, securities of $52M
Aveo Pharmaceuticals in conference presentation slides estimates its Q4 cash and securities at around $52M. Aveo said its streamlined operations by exiting a long term facilities lease and eliminating research functions. It cut its headcount from 60 to 20, which it expects to reduce annual compensation expenses by $6M. The company said it will reduce facilities requirements by up to 80% of its current space, including the elimination of lab and vivarium needs.
06:36 EDTAETAetna to increase wages for lowest-paid workers, WSJ reports
Subscribe for More Information
January 12, 2015
10:40 EDTABCMWI Veterinary Supply postpones 2015 annual meeting of stockholders
Subscribe for More Information
09:00 EDTBMYBristol-Myers price target raised to $70 from $62 at Argus
Subscribe for More Information
08:57 EDTABCAmerisourceBergen says still 'firmly committed' to special repurchase program
Subscribe for More Information
08:51 EDTABCAmerisourceBergen says will use $500M in cash for MWI purchase
Subscribe for More Information
08:50 EDTABCAmerisourceBergen sees reducing regular shares buybacks in FY15 due to deal
Comment from AmerisourceBergen (ABC) call to discuss acquisition of MWI Veterinary Supply (MWIV).
08:37 EDTBMYShire deal suggests most biotech companies in play, says JMP Securities
After Shire (SHPG) agreed to buy NPS Pharmaceuticals (NPSP), JMP Securities says the deal indicates that most biotech companies are in play, particularly those with worldwide rights to their products for well-defined patient populations. The firm expects investors to speculate all week about potential new targets in the space. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
08:22 EDTJPMCiti may have more to gain than JPMorgan from break-up, WSJ says
Analysts have suggested that JPMorgan (JPM) could unlock investor value by breaking-up, but a Citigroup (C) break-up, while complicated, could be more compelling, according to The Wall Street Journal's "Heard on the Street" column. Reference Link
08:15 EDTBMYSeattle Genetics announces clinical trial collaboration with Bristol-Myers
Subscribe for More Information
08:06 EDTBMYBristol-Myers shares expected to trade up around 10% at JPMorgan
JPMorgan expects shares of Bristol-Myers to trade up around 10% after the company announced that its Phase III trial of Opdivo in 2L squamous non-small cell lung cancer is stopping early due to efficacy. The firm views the news as a "clear positive" that sets up a potential 2015 filing and launch for the product in the 2L squamous market. It reiterates an Overweight rating on shares of the Bristol-Myers. The stock is up 7% to $64.25 in pre-market trading.
07:42 EDTABCMWI Veterinary Supply volatility flat into AmerisourceBergen acquiring
MWI Veterinary Supply (MWIV) overall option implied volatility of 30 compares to its 26-week average of 31 according to Track Data, suggesting non-directional price movement into AmerisourceBergen (ABC) acquiring for $190 per share, representing a $2.5B fully diluted equity value.
07:41 EDTJPMLarge banks' weakness creates attractive entry point, says Wells Fargo
Subscribe for More Information
07:34 EDTABCAmerisourceBergen to acquire MWI Veterinary Supply for $190 per share
Subscribe for More Information
07:33 EDTABCAmerisourceBergen to acquire MWI Veterinary Supply for $190 per share
07:17 EDTAVEOJPMorgan to hold a conference
Subscribe for More Information
05:26 EDTBMYBristol-Myers up 5.6% after Opdivo Phase 3 study meets primary endpoint
Subscribe for More Information
05:06 EDTBMYBristol-Myers Opdivo Phase 3 study met primary endpoint
Bristol-Myers Squibb announced that an open-label, randomized Phase 3 study evaluating Opdivo versus docetaxel in previously treated patients with advanced, squamous cell non-small cell lung cancer, or NSCLC, was stopped early because an assessment conducted by the independent Data Monitoring Committee, or DMC, concluded that the study met its endpoint, demonstrating superior overall survival in patients receiving Opdivo compared to the control arm. The company will share these data – which for the first time indicate a survival advantage with an anti-PD1 immune checkpoint inhibitor in lung cancer – with health authorities. CheckMate -017 investigators are being informed of the decision to stop the comparative portion of the trial. Bristol-Myers Squibb is working to ensure that eligible patients will be informed of the opportunity to continue or start treatment with Opdivo in an open-label extension as part of the company’s commitment to providing patient access to Opdivo, and characterizing long-term survival. The company will complete a full evaluation of the final CheckMate -017 data and work with investigators on the future presentation and publication of the results.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use